PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Bioo Scientific

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Bioo Scientific Awarded SBIR Grant for Development of Targeted RNAi in Vivo Delivery Technology - Bioo Scientific received a SBIR Phase II award from the NSF to develop a targeted in vivo RNAi delivery technology
Bioo Scientific Awarded SBIR Grant for Development of Targeted RNAi in Vivo Delivery Technology

 

NewswireToday - /newswire/ - Austin, TX, United States, 2009/07/28 - Bioo Scientific received a SBIR Phase II award from the NSF to develop a targeted in vivo RNAi delivery technology.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Bioo Scientific, an Austin, TX based biotechnology company, announced today that it has been awarded a $500,000 Small Business Innovation Research (SBIR) Phase II grant from the National Science Foundation for the development of a targeted in vivo RNA Interference (RNAi) delivery technology. RNAi is an invaluable technique to characterize gene function and is being evaluated for the treatment of numerous human diseases. According to Lance Ford, Bioo Scientific’s VP of Research and Business Development, “While technologies are widely available for RNAi agent delivery into cells grown on plastic dishes in specially designed incubators, to fully understand gene functions and cellular pathways, in vitro results must be validated in animals. Currently, there are no commercial technologies for the targeted, in vivo delivery of RNAi agents and Bioo Scientific intends to fill this gap”. This grant will enable Bioo Scientific to develop kits and reagents based on the patent-pending Targeted Transport Technology (T3).

T3 involves conjugating an RNAi agent carrier to a monoclonal antibody (mAb) to produce a conjugate, which is then loaded with an RNAi agent such as siRNA and miRNA molecules. The RNAi agent loaded conjugate is administered to an animal where it binds to and is internalized by cells recognized by the mAb. The RNAi agent is then released to reduce the expression of its intended target. T3 will propel the validation of animal experimentation, leading to a better understanding of cellular pathways, the identification of novel drug targets, and the ability to more efficiently deliver RNAi agents as drugs.

About Bioo Scientific Corporation

Bioo Scientific Corporation (biooscientific.com) is an Austin, TX based biotechnology company that provides innovative solutions to the life science industry. Bioo Scientific offers a complete portfolio of products and services for academic, pharmaceutical, biotechnology and molecular diagnostics laboratories, and organizations that perform food and feed safety analysis.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Bioo Scientific

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Bioo Scientific Awarded SBIR Grant for Development of Targeted RNAi in Vivo Delivery Technology

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Dawn Obermoeller 
512-707-8993 dawno[.]biooscientific.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Bioo Scientific securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Bioo Scientific / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

MDxHealth Signs Agreement with Lab21 to Make SelectMDx Liquid Biopsy Test Available in the United Kingdom
Greenphire Drives Global Site Adoption of Clinical Trial Payment Solutions
SelectMDx Chosen by Michigan Medicine as Pre-biopsy Diagnostic Tool in Groundbreaking US Prostate Cancer Risk Clinic
BTG Announces CE Mark Certification for DC Bead LUMI™ - The First Commercially Available Radiopaque Drug-Eluting Bead
Sartorius to Acquire Real-time Live-cell Analysis Pioneer and Leader Essen BioScience
Pyxis™ ES System to Help U.S. Department of Defense Advance Medication Safety and Patient Care
BTG Receives U.S. FDA 510(k) Clearance for EKOS® Control Unit 4.0
MDxHealth Announces Agreement with Istituto Diagnostico Varelli for Distribution of SelectMDx Throughout Central-South Italy
BD Veritor™ System Meets FDA’s New Performance Requirements for Rapid Influenza Antigen Detection Tests
Sub-Sahara Africa - Increase in Western Lifestyles Leads to Dire Need for Chronic Prescription Drugs Finds Frost & Sullivan
BD Initiates New Industry Alliance to Combat Rising Opioid Crisis
BTG and Society of Interventional Oncology to Explore Role of Minimally Invasive Therapies in Immuno-oncology
Ipsen to Acquire a Portfolio of Select Consumer Healthcare Products from Sanofi
BD Announces Early Access Program for BD Resolve™ Single-Cell Analysis Platform
Precision Medicine Unlocks the Future of Targeted Therapy in the Global Healthcare Industry Finds Frost & Sullivan

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  JobsWare.com

Visit  MagLar, Inc.





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)